It’s a great idea to invest in us – and here’s why
Related NewsView All News
Merck KGaA, Darmstadt, Germany, today announced a license agreement with Abbisko Therapeutics for pimicotinib (ABSK021).
We successfully integrated p-Chip's microtransponder technology as a crypto-anchor into a cyber-physical trust framework solution developed by us.
Further develops its biosafety testing laboratories for local demand; New labs complete 2nd phase of company's €29 million Biologics Testing Center.